Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This proposal translates a hypothesis driven basic research into clinical setting to determine the potential of using autologous CD133+ cells to reverse fibrosis and improve clinical outcome for patients with end stage cirrhosis. This has significant impact on the management of cirrhosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National University Hospital, Singapore
• Collaborators: Changi General Hospital; Singapore General Hospital; Tan Tock Seng Hospital

Criteria

Inclusion Criteria:

• Liver cirrhosis of any aetiology but where active disease is controlled

• Childs A/B/C with Child-Pugh score >= 5

And either one of the following:

1. MELD score 10-27

2. Clinically significant portal hypertension as evidenced by gastroesophageal varices or ascites

Exclusion Criteria:

• MELD score >27

• INR>2.5

• HIV

• History of hematological or hepatic malignancy within 5 years from consent

• Other underlying malignancy with <1 year survival

• Presence of systemic diseases that may impact survival within 1 year.

• Listed for liver transplant